JP3040517B2 - Electrophoretic drug permeation device - Google Patents
Electrophoretic drug permeation deviceInfo
- Publication number
- JP3040517B2 JP3040517B2 JP3086002A JP8600291A JP3040517B2 JP 3040517 B2 JP3040517 B2 JP 3040517B2 JP 3086002 A JP3086002 A JP 3086002A JP 8600291 A JP8600291 A JP 8600291A JP 3040517 B2 JP3040517 B2 JP 3040517B2
- Authority
- JP
- Japan
- Prior art keywords
- drug
- ion
- ionic
- electrophoresis
- exchange resin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Electrotherapy Devices (AREA)
Description
【０００１】[0001]
【産業上の利用分野】本発明は、イオン浸透療法（Ion
transter therapy）、即ち、イオン性の薬剤を電気泳動
を利用して薬剤の有効成分をイオンの形で無痛状態で所
望の患部に浸透させる装置に関するものである。The present invention relates to iontophoresis (Ion
The present invention relates to a transter therapy, i.e., a device that uses an electrophoresis to ionically absorb an active ingredient of an ionic drug into a desired diseased part in an ionic form in a painless state.
【０００２】[0002]
【従来の技術】イオン浸透療法は広く知られており、こ
れは大多数の薬剤が電解質（イオン解離性）であること
を利用した治療法である。即ち、薬剤の有効成分が電解
質であり、これを含む水溶液に電場を印加すると、薬剤
の有効成分が水溶液中で陽イオンに解離する場合には当
該陽イオンは陰極へ、陰イオンに解離する場合には当該
陰イオンは陽極へ電気泳動により移動する。従って、こ
の原理によりイオン性薬剤の有効成分（イオン）を無痛
状態で所望の患部に浸透させることができる。2. Description of the Related Art Ion penetration therapy is widely known, and is a treatment method utilizing the fact that most drugs are electrolytes (ion dissociation). That is, when the active ingredient of the drug is an electrolyte and an electric field is applied to an aqueous solution containing the same, the active ingredient of the drug dissociates into a cation in the aqueous solution, and the cation dissociates into a cathode and an anion. Then, the anion moves to the anode by electrophoresis. Therefore, according to this principle, the active ingredient (ion) of the ionic drug can be permeated into a desired affected part in a painless state.
【０００３】これを図面により説明する。図４は薬剤と
してアスコルビン酸ナトリウムを用いて電気泳動により
薬剤の有効成分を皮膚（所望の患部）に浸透させる態様
を説明したもので、従来技術に属するものである。な
お、図４において、アスコルビン酸イオンはＡ-、ナト
リウムイオンはＮａ+、また薬剤のｐＨ安定剤として添
加されるリン酸緩衝溶液中に含まれるリン酸イオンはＨ
2ＰＯ4 -で示されている。図４において、アスコルビン
酸ナトリウム溶液を含浸した薬剤保持材（ガーゼ）を皮
膚（患部）と電源に接続された電極（−極）との間に介
在させ、同様にして他極（＋極）が構成される。このよ
うな状態において電極間に電圧を印加すると次のような
現象が生起する。この場合、薬剤保持材としてのガーゼ
に含浸された薬剤の有効成分であるアスコルビン酸ナト
リウムは、アスコルビン酸イオン（Ａ-）とナトリウム
イオン（Ｎａ+）に解離し、両者は電場によりそれぞれ
の極性とは反対側の電極へ泳動して通電、即ち電流が流
れる。ここで注目しなければならないことは、各イオン
の輸率である。この輸率とは、上例の場合、Ｎａ+の方
が輸率がＡ-と比較して極めて大きく、薬剤の有効成分
であるＡ-のほとんど移動することはない。従って、こ
のような態様では、迅速かつ効果的に薬剤の有効成分を
所望の患部に浸透させることができない。前記した欠点
を解消しようとして、印加電場を大きくすると、電極に
おいて薬剤の有効成分が電極反応を起し、皮膚（患部）
に重大な影響を及ぼす。例えば図４の場合、−極ではア
スコルビン酸の還元分解による有害成分の発生と水素の
発生が生じる。他方、＋極においてはアスコルビン酸の
酸化分解による有害成分の発生と酸素の発生が生じる。
以上の点から、図４に示されるような従来の電気泳動を
利用したイオン浸透法では、薬剤の有効成分を皮膚（患
部）に、それも深部（真皮）まで効率的に浸透させるこ
とができない。This will be described with reference to the drawings. FIG. 4 illustrates an embodiment in which an active ingredient of a drug is permeated into skin (a desired affected area) by electrophoresis using sodium ascorbate as a drug, and belongs to the related art. In FIG. 4, the ascorbate ion is A − , the sodium ion is Na + , and the phosphate ion contained in the phosphate buffer solution added as a pH stabilizer of the drug is H.
2 PO 4 - are indicated by. In FIG. 4, a drug holding material (gauze) impregnated with a sodium ascorbate solution is interposed between the skin (affected part) and an electrode (− pole) connected to a power supply, and the other pole (+ pole) is similarly set. Be composed. When a voltage is applied between the electrodes in such a state, the following phenomenon occurs. In this case, sodium ascorbate, which is an active ingredient of a drug impregnated in gauze as a drug holding material, dissociates into ascorbate ions (A − ) and sodium ions (Na + ), and both of them have respective polarities and polarities depending on an electric field. Migrates to the opposite electrode and conducts electricity, that is, current flows. What should be noted here is the transport number of each ion. And the transference number, if in the above example, transport number who Na + is A - very large compared, is A the active ingredient of the drug - never almost move. Therefore, in such an embodiment, the active ingredient of the drug cannot be quickly and effectively penetrated into the desired affected part. If the applied electric field is increased in order to solve the above-mentioned drawbacks, the active ingredient of the drug causes an electrode reaction at the electrode, and the skin (affected area)
Have a significant effect on For example, in the case of FIG. 4, in the negative electrode, generation of harmful components and generation of hydrogen occur due to reductive decomposition of ascorbic acid. On the other hand, at the positive electrode, generation of harmful components and generation of oxygen occur due to oxidative decomposition of ascorbic acid.
From the above points, the conventional ion permeation method using electrophoresis as shown in FIG. 4 cannot efficiently penetrate the active ingredient of the drug into the skin (affected part) and even into the deep part (dermis). .
【０００４】[0004]
【発明が解決しようとする課題】本発明者らは、前記し
た従来のイオン浸透法の欠点を解消すべき鋭意検討を加
えた。その結果、イオンの透過性に選択性を有するイオ
ン交換樹脂膜を用いることにより、極めて効率的に薬剤
の有効成分を所望の患部に浸透させることができること
を見い出し、本発明を完成するに至った。DISCLOSURE OF THE INVENTION The present inventors have made intensive studies to solve the above-mentioned disadvantages of the conventional ion infiltration method. As a result, they have found that the use of an ion-exchange resin membrane having selectivity in ion permeability makes it possible to infiltrate the active ingredient of a drug into a desired diseased part extremely efficiently, thereby completing the present invention. .
【０００５】[0005]
【課題を解決するための手段】本発明を概説すれば、本
発明は、電気泳動を利用したイオン性薬剤の浸透装置に
おいて、電気泳動用電源部に接続されたイオン性薬剤を
浸透させる側の電極部の構成を、電極、イオン性薬剤の
有効成分のイオンと反対の極性のイオン交換樹脂膜、イ
オン性薬剤を保持する薬剤保持材、イオン性薬剤の有効
成分のイオンと同種の極性のイオン交換樹脂膜、の順に
配設して構成したことを特徴とする電気泳動による薬剤
浸透装置に関するものである。SUMMARY OF THE INVENTION In general, the present invention relates to a device for infiltrating an ionic drug utilizing electrophoresis, on the side where the ionic drug connected to the power supply for electrophoresis penetrates. The configuration of the electrode part is the same as that of the electrode, the ion exchange resin membrane of the opposite polarity to the ion of the active ingredient of the ionic drug, the drug holding material holding the ionic drug, and the ion of the same polarity as the ion of the active ingredient of the ionic drug The present invention relates to a drug permeation device by electrophoresis, wherein the device is arranged in the order of an exchange resin membrane.
【０００６】以下、本発明の技術的構成及び実施の態様
について図面を参照して説明する。なお、本発明は、図
示のものに限定されないことはいうまでもないことであ
る。Hereinafter, a technical configuration and embodiments of the present invention will be described with reference to the drawings. It is needless to say that the present invention is not limited to the illustrated one.
【０００７】本発明の最大の特徴は、前記したように電
気泳動を利用したイオン性薬剤の浸透装置において、特
に、電気泳動用電源部に接続されたイオン性薬剤を浸透
させる側の電極部（作用側電極部）の構成において、従
来のように電極上に、単にイオン性薬剤を保持するため
の薬剤保持材を配設するのではなく、当該薬剤保持材と
ともにイオン性薬剤の有効成分のイオンと同種及び異種
の極性の二種のイオン交換樹脂膜を配設した点にある。The most significant feature of the present invention is that, as described above, in the ionic drug infiltration apparatus utilizing electrophoresis, in particular, the electrode section on the side for penetrating the ionic drug connected to the power supply for electrophoresis ( In the configuration of the working electrode section), instead of simply disposing a drug holding material for holding the ionic drug on the electrode as in the conventional case, the ion holding of the active ingredient of the ionic drug together with the drug holding material is performed. And two types of ion exchange resin membranes having the same and different polarities.
【０００８】本発明の前記したイオン交換樹脂膜を使用
することの優位性について、以下、図１〜図２を参照し
て説明する。The advantages of using the above-described ion exchange resin membrane of the present invention will be described below with reference to FIGS.
【０００９】図１は、電気泳動によるイオン性薬剤の浸
透装置において、電気泳動用電源部に接続されたイオン
性薬剤を浸透させる側の作用電極部の構成として、−極
（負極）板上に薬剤保持材であるガーゼ、更に該ガーゼ
の上にアニオン交換樹脂膜を配設て構成したものを示し
ている。なお、図１は、−極（負極）側を患部側の皮膚
に当接させてイオン性薬剤を浸透させることを前提とし
ており、従って一極側は作用電極部となるものである。
一方、＋極（正極）側はアース（接地）電極部となるこ
とはいうまでもないことである。また、図４と同様に薬
剤としてアスコルビン酸ナトリウムの水溶液を用いてい
る。FIG. 1 shows an apparatus for penetrating an ionic drug by electrophoresis, in which a working electrode connected to an electrophoresis power supply unit on the side where the ionic drug penetrates is formed on a negative (negative) plate. The figure shows a gauze which is a medicine holding material, and further comprises an anion exchange resin membrane disposed on the gauze. Note that FIG. 1 is based on the premise that the negative electrode (negative electrode) is brought into contact with the skin on the affected part side to allow the ionic drug to penetrate, and therefore the one electrode side is a working electrode part.
On the other hand, it goes without saying that the positive (positive) side is an earth (ground) electrode portion. In addition, an aqueous solution of sodium ascorbate is used as a drug as in FIG.
【００１０】図１は、図示の態様でアニオン交換膜を用
いているため、前記従来技術に係わる図４のものと相違
して作用電極部では皮膚面に存在する汗中のＮａ＋がア
ニオン交換膜中を通過せず、イオン性薬剤の有効成分で
あるアニオン（アスコルビン酸イオンＡ−）が皮膚側へ
の移動することを示している。なお、図４は、皮膚面側
へのＡ−の移動のほかに、皮膚面に存在するＮａ＋が一
極側へ移動することを示している。前記したことから明
らかのように、アニオン交換膜は、電気泳動現象を用い
てアスコルビン酸、より正確にはイオン性薬剤の有効成
分であるアスコルビン酸イオン（Ａ−）を皮膚（患部）
に投与するうえで大きな寄与をなしているものである。FIG. 1 uses an anion-exchange membrane in the illustrated embodiment, so that Na + in the sweat present on the skin surface is anion-exchanged at the working electrode portion, unlike the prior art of FIG. This indicates that the anion (ascorbate ion A − ), which is an active ingredient of the ionic drug, does not pass through the membrane and moves to the skin side. FIG. 4 shows that, in addition to the movement of A − to the skin surface side, Na + present on the skin surface moves to the monopolar side. As is clear from the above, the anion exchange membrane uses the electrophoresis phenomenon to convert ascorbic acid, more precisely, ascorbate ion (A − ), which is an active ingredient of an ionic drug, into the skin (affected area).
Is a major contributor in the administration of
【００１１】本発明において、イオン交換樹脂膜を配設
する態様は、前記図１に示されるものではなく、図２に
示される態様を採用する点に大きな特徴点がある。図２
は、前記図１のイオン交換膜の配設態様のものと比較す
ると、更に−極側にカチオン交換膜を配設している点で
大きく異なる。図２のイオン交換膜の配設態様、即ち、
アニオン及びカチオンの二種のイオン交換膜を配設する
場合、印加電圧を図１のものよりも大きくしても、アス
コルビン酸の−極上での電極反応を抑制することがで
き、かつ、−極上での水の電気分解反応（還元）により
生成するＯＨ−（ヒドロキシイオン）の皮膚面への移動
を阻止することができる。即ち、印加電圧を大きくして
も、カチオン交換膜によりイオン性薬剤の有効成分であ
るアスコルビン酸イオン（Ａ−）の−極側への移動や接
触がカチオン交換膜により阻止され、−極上での電極反
応（アスコルビン酸の分解）は防止される。また、一極
上での水の電気分解反応（還元）により生成するＯＨ−
（ヒドロキシイオン）は、カチオン交換膜により皮膚面
への移動が阻止され、皮膚面での急激なｐＨ値上昇（高
アルカリ化）による皮膚のやけどなどの欠点が防止され
る。従って、本発明の図２に示されるイオン交換膜の配
設態様により、イオン性薬剤の有効成分であるアスコル
ビン酸イオン（Ａ−）を効果的かつ効率的に所望患部に
浸透させることができる。In the present invention, the mode of disposing the ion-exchange resin membrane is not the one shown in FIG. 1 but has a significant feature in adopting the mode shown in FIG. FIG.
Is significantly different from that of the above-described arrangement of the ion exchange membrane in FIG. 1 in that a cation exchange membrane is further disposed on the negative electrode side. The arrangement mode of the ion exchange membrane of FIG.
When two types of ion exchange membranes of an anion and a cation are provided, the electrode reaction of ascorbic acid on the negative electrode can be suppressed even if the applied voltage is higher than that in FIG. OH − (hydroxy ions) generated by the electrolysis reaction (reduction) of water at the surface can be prevented from moving to the skin surface. That is, even if the applied voltage is increased, the cation exchange membrane prevents ascorbate ion (A − ), which is an active ingredient of the ionic drug, from moving or contacting to the negative electrode side by the cation exchange membrane. Electrode reactions (decomposition of ascorbic acid) are prevented. In addition, OH − generated by the electrolysis reaction (reduction) of water on one pole
(Hydroxy ions) are prevented from moving to the skin surface by the cation exchange membrane, and defects such as burns on the skin due to a rapid increase in the pH value (high alkalinity) on the skin surface are prevented. Therefore, according to the arrangement of the ion exchange membrane shown in FIG. 2 of the present invention, ascorbate ion (A − ), which is an active ingredient of an ionic drug, can be effectively and efficiently penetrated into a desired diseased part.
【００１２】本発明において、一極側（作用電極部側）
に配設するイオン選択性の異なる二種のイオン交換膜の
配設態様は、図２から明らかのようにイオン性薬剤の有
効成分の極性に依存することはいうまでもないことであ
る。即ち、イオン性薬剤が図２に示されるアニオンに解
離するアスコルビン酸ナトリウム（Ａ−Ｎａ＋）の場
合、薬剤保持材（ガーゼ）の皮膚側に面する側にアニオ
ン交換膜、その反対側（−極側）にカチオン交換膜を配
設すればよい。また、イオン性薬剤がカチオンに解離す
る場合、作用電極部の極性を＋極にするとともに、薬剤
保持材（ガーゼ）の皮膚側に面する側にカチオン交換
膜、その反対側（＋極側）にアニオン交換膜を配設すれ
ばよい。In the present invention, one electrode side (working electrode part side)
Needless to say, the arrangement of the two types of ion exchange membranes having different ion selectivities depends on the polarity of the active ingredient of the ionic drug, as is clear from FIG. That is, when the ionic drug is sodium ascorbate (A - Na + ) which dissociates into the anion shown in FIG. 2, an anion exchange membrane is provided on the side of the drug holding material (gauze) facing the skin, and the opposite side (− The cation exchange membrane may be provided on the (electrode side). In addition, when the ionic drug dissociates into cations, the polarity of the working electrode portion is set to a positive polarity, and a cation exchange membrane is provided on the side of the drug holding material (gauze) facing the skin, and the opposite side (the positive pole side) May be provided with an anion exchange membrane.
【００１３】前記したイオン交換樹脂膜としては、通常
のものを使用すればよく、特に制限を受けるものではな
い。例えば、アニオン交換膜としては高分子の側鎖に四
級化されたアンモニウム基を有するもの、カチオン交換
膜としては高分子の側鎖にスルホン酸基を有するものな
どを使用すればよく、これらは図２に示されるようにイ
オン性薬剤の解離イオン種の種類によって適宜組合わせ
て使用される。As the above-mentioned ion exchange resin membrane, a usual one may be used, and there is no particular limitation. For example, an anion exchange membrane having a quaternized ammonium group in the side chain of the polymer, and a cation exchange membrane having a sulfonic acid group in the side chain of the polymer may be used. As shown in FIG. 2, the ionic drug is used in combination as appropriate depending on the type of dissociated ion species.
【００１４】本発明において、医薬用薬剤としてはイオ
ン解離し電気泳動するものは全て使用できるが、これら
の有効成分がどのようにイオン解離しているかにより、
使用するイオン交換樹脂膜を選べばよい。通常、よく使
用される薬剤において、陽極性のものは局所麻酔（コカ
イン、ノボカイン、ナルカイン）、ヨードカリ、塩化カ
ルシウム、ヒスタミン、各種ビタミン（Ｂ１，Ｃな
ど）、陰極性のものは、クロール（腐食剤）、チトラー
ト（鎮痛剤）、ヨウ化カリウム、ペニシリンなどがあ
る。これらの薬剤の極性にあわせて使用するイオン交換
樹脂膜を選べばよい。In the present invention, any drug capable of ion dissociation and electrophoresis can be used as a pharmaceutical agent, but depending on how these active ingredients are ion dissociated,
What is necessary is just to select the ion exchange resin membrane to be used. Of the commonly used drugs, anodically used ones are locally anesthetized (cocaine, novocaine, narcaine), iodocali, calcium chloride, histamine, various vitamins (B1, C, etc.), and cathodic ones are chlor (corrosive agent) ), Titrates (analgesics), potassium iodide, penicillin and the like. The ion exchange resin membrane to be used may be selected according to the polarity of these agents.
【００１５】図３に、本発明の電気泳動による薬剤浸透
装置の概略図を示す。図３に示される本発明の薬剤浸透
装置（１）は、電気泳動用電源部（２）を本体内部に有
し、該電源部（２）に接続されたイオン性薬剤を浸透さ
せる作用電極部を有するものであって、該作用電極部の
構成が、電極（３）、該電極（３）上面に薬剤保持材
（４）、更にその上部に薬剤保持材（４１）を挟持した
二枚のイオン交換樹脂膜（５，５１）、最上部に薬剤保
持材（４２）を配設することにより構成されたものであ
る。FIG. 3 is a schematic view of a drug permeation apparatus using electrophoresis according to the present invention. The drug permeation apparatus (1) of the present invention shown in FIG. 3 has a power supply section for electrophoresis (2) inside a main body, and a working electrode section for permeating an ionic drug connected to the power supply section (2). The working electrode portion is composed of an electrode (3), a drug holding material (4) on the upper surface of the electrode (3), and a drug holding material (41) sandwiched between the electrodes (3). An ion exchange resin membrane (5, 51) is provided by disposing a drug holding material (42) at the top.
【００１６】図３に示されるように、薬剤浸透装置
（１）の前面部に配設される電極（３）と薬剤保持材
（４）は蓋受部（６）により包囲され、かつ、該蓋受部
（６）には蓋体（７）が固定されている。蓋受部（６）
と蓋体（７）が、固定される位置で薬剤保持材（４，４
１，４２）に含浸された薬液が他部へ漏れないようにパ
ッキン（８）が施されている。しかし、本発明において
これらの蓋受部（６）と蓋体（７）などの構造は所望の
ものでよく、その固定手段も螺合式、フック式などいず
れであってもよい。また、図３において、電極（３１）
は、接地（アース）側の電極を示すものである。As shown in FIG. 3, the electrode (3) and the medicine holding material (4) disposed on the front surface of the medicine permeation device (1) are surrounded by a lid receiving part (6). A lid (7) is fixed to the lid receiving portion (6). Lid receiver (6)
The medicine holding material (4, 4)
A packing (8) is provided so that the chemical solution impregnated in (1, 42) does not leak to other parts. However, in the present invention, the structure such as the lid receiving portion (6) and the lid (7) may be any desired structure, and the fixing means may be any type such as a screw type or a hook type. Also, in FIG. 3, the electrodes (31)
Indicates an electrode on the ground (earth) side.
【００１７】前記図３に示される薬剤浸透装置（１）に
おいて、薬剤保持材としては、ガーゼ、脱脂あるいは生
理綿、合成樹脂製のスポンジ材などによりイオン性薬剤
の溶液を保持できるものであればいずれでもよい。In the drug infiltration apparatus (1) shown in FIG. 3, as a drug holding material, any material can be used which can hold a solution of an ionic drug by using a gauze, degreased or sanitary cotton, synthetic resin sponge material, or the like. Either may be used.
【００１８】前記したように電気泳動効果により薬物を
投与する場合、投与する量は流れた電気量と関連してお
り、特にイオン交換樹脂膜を用いて選択的に投与を行な
う場合には、簡単に投与量を見積ることができる。例え
ば、本発明の薬剤浸透装置を用いてアスコルビン酸（分
子量１８１）を１ｍｇ投与しようとする場合、電流を
０．５ｍＡとし約２０分程度という極めて短時間に効率
的に投与することができる。As described above, when administering a drug by the electrophoretic effect, the amount to be administered is related to the amount of electricity flowing, and particularly when the administration is selectively performed using an ion-exchange resin membrane, the administration is simple. The dose can be estimated. For example, when trying to administer 1 mg of ascorbic acid (molecular weight: 181) using the drug permeation device of the present invention, the current can be efficiently administered in an extremely short time of about 20 minutes at 0.5 mA.
【００１９】[0019]
【発明の効果】本発明の電気泳動による薬剤浸透装置
は、次のような優れた効果を有する。 (i) 薬剤のイオン解離性有効成分を迅速、適確に電気泳
動により皮膚（患部）に浸透させることができる。 (ii)電極上での薬剤成分及び水（電極液）の電気化学反
応（電極反応）を防止できたり、該電気化学反応により
生成する皮膚に対する有害物質の皮膚側への移動を防止
することができるため極めて安全である。 (iii)薬物の有効成分のイオン極性に応じて、最適なイ
オン交換樹脂膜を選べることができるため、あらゆる薬
剤を効率よく皮膚（患部）に浸透させることができる。The drug permeation apparatus using electrophoresis of the present invention has the following excellent effects. (i) The ion-dissociable active ingredient of a drug can be quickly and accurately penetrated into skin (affected part) by electrophoresis. (ii) It is possible to prevent an electrochemical reaction (electrode reaction) between a drug component and water (electrode solution) on the electrode, and to prevent a harmful substance generated on the skin from the electrochemical reaction from moving to the skin side. It is extremely safe because it can be done. (iii) Since an optimal ion exchange resin membrane can be selected according to the ionic polarity of the active ingredient of the drug, any drug can be efficiently penetrated into the skin (affected part).
【図１】 アニオン性イオン交換樹脂膜を利用した薬剤
浸透装置におけるイオン性薬剤の電気泳動過程を説明す
る図である。FIG. 1 is a diagram illustrating an electrophoretic process of an ionic drug in a drug permeation device using an anionic ion exchange resin membrane.
【図２】 本発明のアニオン性及びカチオン性イオン交
換樹脂膜を利用した薬剤浸透装置におけるイオン性薬剤
の電気泳動過程を説明する図である。FIG. 2 is a diagram illustrating an electrophoretic process of an ionic drug in a drug permeation apparatus using an anionic or cationic ion exchange resin membrane of the present invention.
【図３】 本発明の薬剤浸透装置の概要図である。FIG. 3 is a schematic diagram of a drug permeation device of the present invention.
【図４】 従来の薬剤浸透装置における、薬剤の電気泳
動勝ち得を説明する図である。FIG. 4 is a diagram for explaining the electrophoresis of a drug in a conventional drug permeation apparatus.
１ ………………………… 薬剤浸透装置 ２ ………………………… 電気泳動用電源部 ３，３１ ………………… 電極 ４，４１，４２ ………… 薬剤保持材 ５，５１ ………………… イオン交換膜 1 ………………………………………………………………………………………………………… Electrophoresis power supply 3,31 ……………… Electrodes 4,41,42 ……… Drug holding material 5,51 ………………… Ion exchange membrane
Claims (4)
装置において、電気泳動用電源部に接続されたイオン性
薬剤を浸透させる側の電極部の構成を、電極、イオン性
薬剤の有効成分のイオンと反対の極性のイオン交換樹脂
膜、イオン性薬剤を保持する薬剤保持材、イオン性薬剤
の有効成分のイオンと同種の極性のイオン交換樹脂膜、
の順に配設して構成したことを特徴とする電気泳動によ
る薬剤浸透装置。1. An ionic drug infiltration apparatus utilizing electrophoresis, wherein the configuration of an electrode portion on the side for penetrating the ionic drug, which is connected to a power supply for electrophoresis, comprises an electrode and an active component of the ionic drug. Ion exchange resin membrane of opposite polarity to ion, drug holding material to hold ionic drug, ion exchange resin membrane of same polarity as ion of active ingredient of ionic drug,
A drug permeation device by electrophoresis, wherein the device is arranged in the order of:
性イオン交換樹脂膜の間に薬剤保持材が介装されたもの
である請求項第１項に記載の電気泳動による薬剤浸透装
置。2. The electrophoretic drug permeation apparatus according to claim 1, wherein a drug holding material is interposed between the cationic ion exchange resin membrane and the anionic ion exchange resin membrane.
と反対の極性のイオン交換樹脂膜との間に、薬剤保持材
が介装されたものである請求項第１項に記載の電気泳動
による薬剤浸透装置。3. The electrophoresis according to claim 1, wherein a drug holding material is interposed between the electrode and an ion exchange resin membrane having a polarity opposite to that of the ion of the active ingredient of the ionic drug. By drug infiltration device.
の極性のイオン交換樹脂膜の前面側に、薬剤保持材が配
設されたものである請求項第１項に記載の電気泳動によ
る薬剤浸透装置。4. The drug by electrophoresis according to claim 1, wherein a drug holding material is provided on the front side of an ion exchange resin membrane having the same polarity as the ion of the active ingredient of the ionic drug. Infiltration equipment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3086002A JP3040517B2 (en) | 1991-03-27 | 1991-03-27 | Electrophoretic drug permeation device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3086002A JP3040517B2 (en) | 1991-03-27 | 1991-03-27 | Electrophoretic drug permeation device |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH04297277A JPH04297277A (en) | 1992-10-21 |
| JP3040517B2 true JP3040517B2 (en) | 2000-05-15 |
Family
ID=13874465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3086002A Expired - Fee Related JP3040517B2 (en) | 1991-03-27 | 1991-03-27 | Electrophoretic drug permeation device |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3040517B2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006112254A1 (en) * | 2005-04-15 | 2006-10-26 | Transcu Ltd. | External preparation, method of applying external preparation, iontophoresis device and transdermal patch |
| US7660626B2 (en) | 2005-02-03 | 2010-02-09 | Tti Ellebeau, Inc. | Iontophoresis device |
| US7890164B2 (en) | 2005-09-15 | 2011-02-15 | Tti Ellebeau, Inc. | Iontophoresis device |
| US8062783B2 (en) | 2006-12-01 | 2011-11-22 | Tti Ellebeau, Inc. | Systems, devices, and methods for powering and/or controlling devices, for instance transdermal delivery devices |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ532402A (en) | 2001-10-31 | 2005-11-25 | Transcutaneous Tech Inc | Iontophoresis device |
| EP1566197A4 (en) | 2002-11-27 | 2008-07-09 | Tokuyama Corp | Iontophoresis apparatus |
| JP2004202057A (en) | 2002-12-26 | 2004-07-22 | Tokuyama Corp | Ionic medicine encapsulation bag |
| WO2004080441A1 (en) | 2003-03-10 | 2004-09-23 | Tokuyama Corporation | Patch material for ionic medicine administration |
| JP2006116086A (en) | 2004-10-21 | 2006-05-11 | Tokuyama Corp | Action pole structure for iontophoresis apparatus and iontophoresis apparatus |
| CA2623660A1 (en) | 2005-09-30 | 2007-04-05 | Tti Ellebeau, Inc. | Electrode structure for iontophoresis used to administer drug enclosed in nanoparticle and iontophoresis device making use of the same |
| EP1941929A1 (en) | 2005-09-30 | 2008-07-09 | Tti Ellebeau, Inc. | Electrode structure for iontophoresis comprising shape memory separator, and iontophoresis apparatus comprising the same |
| EP1944057A4 (en) | 2005-09-30 | 2009-02-18 | Tti Ellebeau Inc | Iontophoresis apparatus capable of controlling dose and timing of administration of sleep inducer and analeptic agent |
| JPWO2007043605A1 (en) | 2005-10-12 | 2009-04-16 | Ｔｔｉ・エルビュー株式会社 | Mucoadhesive iontophoresis device |
| JP4732881B2 (en) * | 2005-12-07 | 2011-07-27 | Ｔｔｉ・エルビュー株式会社 | Iontophoresis device |
| JP4805693B2 (en) | 2006-03-01 | 2011-11-02 | Ｔｔｉ・エルビュー株式会社 | Iontophoresis device and manufacturing method thereof |
| WO2008030496A2 (en) | 2006-09-05 | 2008-03-13 | Tti Ellebeau, Inc. | Non-destructive systems, devices, and methods for evaluating iontophoresis drug delivery devices |
| JPWO2008044705A1 (en) | 2006-10-10 | 2010-02-12 | Ｔｔｉ・エルビュー株式会社 | Denture iontophoresis device |
-
1991
- 1991-03-27 JP JP3086002A patent/JP3040517B2/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7660626B2 (en) | 2005-02-03 | 2010-02-09 | Tti Ellebeau, Inc. | Iontophoresis device |
| WO2006112254A1 (en) * | 2005-04-15 | 2006-10-26 | Transcu Ltd. | External preparation, method of applying external preparation, iontophoresis device and transdermal patch |
| US7890164B2 (en) | 2005-09-15 | 2011-02-15 | Tti Ellebeau, Inc. | Iontophoresis device |
| US8062783B2 (en) | 2006-12-01 | 2011-11-22 | Tti Ellebeau, Inc. | Systems, devices, and methods for powering and/or controlling devices, for instance transdermal delivery devices |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH04297277A (en) | 1992-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3040517B2 (en) | Electrophoretic drug permeation device | |
| JP4361153B2 (en) | Iontophoresis device | |
| RU2269366C2 (en) | Iontophoresis apparatus | |
| US6289241B1 (en) | Method and apparatus for controlled environment electrotransport | |
| US5125894A (en) | Method and apparatus for controlled environment electrotransport | |
| Bellantone et al. | Enhanced percutaneous absorption via iontophoresis I. Evaluation of an in vitro system and transport of model compounds | |
| EP0435436B1 (en) | Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals | |
| JP2000229129A (en) | Method for administering ionic drug by iontophoresis | |
| JPWO2007026672A1 (en) | Versatile electrolyte composition for iontophoresis | |
| JPH07504342A (en) | Electrochemical methods and devices for drug delivery | |
| JP2000237327A (en) | Administration method of ionic medicine by iontophoresis | |
| WO2006112254A1 (en) | External preparation, method of applying external preparation, iontophoresis device and transdermal patch | |
| JP2000237328A (en) | Iontophoresis apparatus | |
| JP2006149891A (en) | Iontophoresis apparatus | |
| AU2005310701A1 (en) | Iontophoresis device | |
| JP2000237329A (en) | Administration method of ionic medicine by iontophoresis | |
| JP4361155B2 (en) | Iontophoresis device | |
| EP1932562A1 (en) | Iontophoresis apparatus | |
| EP1820533B1 (en) | Ion-tophoretic apparatus | |
| Miller et al. | Iontophoretic transport of acetate and carboxylate ions through hairless mouse skin. A cation exchange membrane model | |
| JP2000288097A (en) | Iontophorese apparatus | |
| WO1997012644A1 (en) | Improved iontophoretic reservoir apparatus | |
| JP2905980B2 (en) | Iontophoresis electrode | |
| Hirvonen et al. | Current profile regulates iontophoretic delivery of amino acids across the skin | |
| CA2618382A1 (en) | Iontophoresis device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R154 | Certificate of patent or utility model (reissue) |
Free format text: JAPANESE INTERMEDIATE CODE: R154 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080303 Year of fee payment: 8 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080303 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090303 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090303 Year of fee payment: 9 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090303 Year of fee payment: 9 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090303 Year of fee payment: 9 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090303 Year of fee payment: 9 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090303 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100303 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100303 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110303 Year of fee payment: 11 |
|
| LAPS | Cancellation because of no payment of annual fees |